Hypothesis

Chronic analgesic use blunts a hormetic pain signal that normally activates endothelial NAD+ salvage via TRPV1‑Ca2+/CAMKK2‑AMPK‑SIRT1 signaling, leading to reduced ADAMTS13 transcription, impaired von Willebrand factor clearance, and an accelerated prothrombotic state that drives inflammaging and mortality.

Mechanistic Rationale

1. Pain as a NAD+‑boosting cue – Acute pain triggers TRPV1-mediated calcium influx in endothelial cells, activating CAMKK2‑AMPK and subsequently SIRT1. SIRT1 deacetylates and stabilizes the transcription factor FOXO3, which drives expression of NAMPT, the rate‑limiting enzyme in the NAD+ salvage pathway (3). Elevated NAD+ fuels SIRT1 and PARP activity, promoting DNA repair and anti‑inflammatory gene programs.
2. NAD+‑dependent ADAMTS13 upregulation – SIRT1 directly deacetylates the ADAMTS13 promoter enhancer region, increasing its transcription. Higher ADAMTS13 activity cleaves ultra‑large VWF multimers, preventing excessive platelet adhesion (7).
3. Analgesic interference – NSAIDs inhibit COX‑derived prostaglandins that sensitize TRPV1, while opioids cause μ‑opioid receptor‑mediated G‑protein bias that reduces TRPV1 channel opening and downstream calcium signaling. Both classes therefore dampen the pain‑evoked NAD+ surge.
4. Consequence of NAD+ depletion – Lower NAD+ reduces SIRT1 activity, decreasing FOXO3‑NAMPT signaling and ADAMTS13 expression. Consequently, VWF:Ag accumulates, thrombin generation rises (8), and the endothelium adopts a prothrombotic phenotype.
5. Feedback to inflammaging – Elevated VWF and thrombin activate PAR‑1 on monocytes, amplifying NF‑κB‑driven IL‑6 and TNF‑α production (4). This creates a vicious loop where inflammation further suppresses pain perception, reinforcing analgesic dependence.

Testable Predictions

• Human cohort – In adults ≥60 y, regular analgesic users (≥3 doses/week for >6 mo) will show a steeper annual increase in plasma VWF:Ag (+1.2 IU/dL/y) and D‑dimer (+0.05 µg/mL/y) compared with matched non‑users, after adjusting for baseline IL‑6, BMI, and comorbidities.
• Intervention – A 12‑week randomized trial adding a low‑dose TRPV1 agonist (e.g., capsazepine‑nanoparticle) to standard analgesic therapy will preserve NAD+ levels (measured in peripheral blood mononuclear cells) and attenuate the rise in VWF:Ag relative to placebo‑analgesic controls.
• Mechanistic biomarker – SIRT1 activity in circulating endothelial‑derived extracellular vesicles will mediate the relationship between analgesic exposure and ADAMTS13 activity (sobel test p < 0.01).

Falsifiability

If longitudinal data reveal no difference in VWF:Ag trajectories between chronic analgesic users and non‑users, or if TRPV1 agonism fails to rescue NAD+ or ADAMTS13 levels, the hypothesis is refuted. Conversely, confirmation would support re‑evaluating analgesic prescribing practices in older adults to preserve pain‑driven hormetic signaling.